Project Grant K22AI191864
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $489,500 to The Children's Hospital of Philadelphia Research Institute on June 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This two-year project, which extends through May 31, 2027, focuses on developing novel sequencing methodologies and analytical pipelines to identify and characterize intact human immunodeficiency virus (HIV) reservoir cells...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Washington University $650,934 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a one-year project period commencing August 1, 2025, and concluding July 31, 2026. This Project Grant supports mechanistic research investigating how HIV-1 Gag/matrix proteins sequester the CARD8 inflammasome, with the objective of developing targeted therapeutic strategies for...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $672,248 Project Grant effective September 15, 2025, through August 31, 2030, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This research initiative, led by co-principal investigators Dr. Eileen Scully at Johns Hopkins University and Dr. Ronald Galiwango at the Rakai Health Sciences Program, focuses on HIV reservoir dynamics and immune...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $238,972 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation for the State University of New York, effective July 28, 2025, with completion anticipated by June 30, 2027. This award supports basic biomedical research investigating the mechanism by which EPS15 Homology Domain Protein 4 (EHD4) functions as an HIV-1 restriction...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Salk Institute for Biological Studies a Project Grant of $188,208 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for structural and biochemical studies of human immunodeficiency virus (HIV) and mouse mammary tumor virus (MMTV) retroviral integration. The award, obligated on October 24, 2025, with completion scheduled for June 30, 2028, supports research to elucidate...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pennsylvania $3,643,653 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 8, 2025, for a project-based research initiative extending through May 31, 2030. This award supports a multi-project consortium focused on developing chimeric antigen receptor (CAR) T cell therapies to achieve durable control of human immunodeficiency virus (HIV) replication...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Washington University a Project Grant totaling $592,106 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective March 1, 2025, with a completion date of February 28, 2030. This award supports a five-year research initiative focused on understanding the molecular mechanisms underlying tropism-specific immune restriction in Human Immunodeficiency Virus (HIV)...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pennsylvania a $891,410 Project Grant effective August 14, 2025, through July 31, 2030, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award supports research into therapeutic vaccination strategies designed to enhance autologous neutralizing antibody (ANAB) responses in people with human immunodeficiency virus (HIV) to achieve antiretroviral...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $240,000 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 3, 2025, with a completion date of August 31, 2027. The research initiative focuses on characterizing HIV-1 viral reservoirs through a newly developed viral immunocapture pipeline that combines immunological and genomic...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Washington University $999,100 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 15, 2025, with a completion date of April 30, 2027. This Project Grant funds biomedical research investigating the mechanisms by which BACH2 (BTB domain and CNC homolog 2) controls long-lived human immunodeficiency virus (HIV) cellular reservoirs in memory CD4+ T cells. The research...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded $162,000 to The Wistar Institute of Anatomy and Biology on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the project "Defining the Single-Cell Epigenetic Landscape of the HIV-1 Reservoir for Effective Latency Reversal." The project, which will be completed by January 31, 2028, focuses on advancing scientific understanding of how Human Immunodeficiency Virus (HIV) establishes latency at the epigenetic level—specifically examining how integrated viral DNA (proviruses) is regulated through chromatin accessibility and condensation patterns. This research addresses a critical gap in HIV cure strategies, as current latency reversal pharmacological agents achieve only partial reactivation of HIV-infected cells, limiting the efficacy of interventional elimination therapies. The research deliverables include characterization of the epigenetic heterogeneity of latent HIV proviruses using single-cell analysis techniques to distinguish between transcriptionally silent proviruses in condensed (heterochromatic) DNA versus those in more accessible (euchromatic) regions. By mapping the single-cell epigenetic landscape of the HIV-1 reservoir, this work will provide foundational knowledge to inform the development of more efficient latency reversal strategies that could enable complete reactivation of infected cells and support the advancement toward functional HIV cures, thereby reducing lifetime dependency on antiretroviral therapy and associated long-term health complications for people with HIV.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/13/26 | ||
| Not listed | $162.0k | 2/5/26 |